Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 28, 2026 08:00 ET | Source: Actinogen Medical

Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program

SYDNEY, May 28, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) today announces the successful outcome of its scheduled scientific advice meeting (written response) on Alzheimer’s...
May 28, 2026 05:22 ET | Source: InnoCare Pharma

InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China

This is the first NDA acceptance for BTK inhibitor orelabrutinib in autoimmune diseases. No BTK inhibitors have been approved in China for ITP.
May 27, 2026 17:02 ET | Source: kneat.com, inc.

Kneat Announces Results of Voting at Annual General Meeting

Kneat shareholders elect board of directors, approve auditors at Kneat's Annual General Meeting today
May 27, 2026 16:00 ET | Source: Cytokinetics, Incorporated

Cytokinetics to Participate in June Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following...
May 27, 2026 10:00 ET | Source: Therini Bio, Inc.

Therini Bio Doses First Patients in Phase 1b Trial of Novel Anti-Inflammatory Therapy, THN391, for Diabetic Macular Edema

Therini Bio doses first patients in Ph1b trial evaluating novel anti-inflammatory therapy, THN391, in DME, and advances fibrin/VEGF bispecific THN622
May 27, 2026 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH

Growing body of clinical and real-world evidence supports the role of Rezdiffra® (resmetirom) as the foundational therapy for patients with MASH Rezdiffra improved atherogenic lipid profiles...
May 27, 2026 07:13 ET | Source: Reprogram Biosciences, Inc.

Reprogram Biosciences Closes Seed Financing to Advance Tumor Cell Reprogramming Therapeutics

Reprogram Biosciences closed its seed financing, bringing total capital raised to $6 million since founding.
May 27, 2026 06:02 ET | Source: InnoCare Pharma

InnoCare Announces Approval of Orelabrutinib in Australia

Orelabrutinib (HIBRUKA®) has been approved by TGA in Australia, offering a new treatment option for patients with R/R MCL in the region.
May 26, 2026 16:10 ET | Source: Spyre Therapeutics, Inc.

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to...
May 26, 2026 08:30 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces 1-for-10 Reverse Share Split

Grand Cayman, May 26, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi)...